A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
Inclusion Criteria:
Exclusion Criteria:
Fort Gratiot, Michigan 48059, United States
Caba, C1122AAF, Argentina
Caba, C1199ABD, Argentina
CABA, C1425BEA, Argentina
Borgyogyaszati Klinika, 7632, Hungary
Szeged, 6720, Hungary
Gunma, 371 8511, Japan
Hokkaido, 060-0033, Japan
Hokkaido, 078 8510, Japan
Itabashi Ku, 173 8606, Japan
Kitakyushu-shi, 807-8556, Japan
Obihiro Shi, 080 0013, Japan
Osaka, 550 0006, Japan
Takaoka Shi, 933-0871, Japan
Elblag, 82 300, Poland
Krakow, 30-002, Poland